Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1950 1
1951 4
1953 3
1954 5
1955 6
1956 10
1957 9
1958 10
1959 6
1960 14
1961 22
1962 27
1963 39
1964 101
1965 50
1966 57
1967 59
1968 76
1969 86
1970 72
1971 95
1972 69
1973 103
1974 106
1975 120
1976 107
1977 128
1978 126
1979 133
1980 117
1981 108
1982 157
1983 157
1984 178
1985 191
1986 193
1987 190
1988 170
1989 230
1990 195
1991 204
1992 206
1993 168
1994 216
1995 219
1996 233
1997 221
1998 219
1999 214
2000 263
2001 207
2002 236
2003 252
2004 259
2005 265
2006 309
2007 298
2008 305
2009 310
2010 324
2011 317
2012 379
2013 349
2014 393
2015 346
2016 383
2017 322
2018 300
2019 337
2020 353
2021 324
2022 301
2023 249
2024 126

Text availability

Article attribute

Article type

Publication date

Search Results

11,962 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for sarcolysin
Search for sarcolysis instead (2 results)
[The effect of lipid derivative of anti-tumor drug sarcolysin embedded in phospholipid nanoparticles in the experiments in vivo].
Tereshkina YA, Torkhovskaya TI, Sanzhakov MA, Kostryukova LV, Khudoklinova YY, Tikhonova EG. Tereshkina YA, et al. Biomed Khim. 2021 Nov;67(6):491-499. doi: 10.18097/PBMC20216706491. Biomed Khim. 2021. PMID: 34964443 Russian.
To improve the therapeutic properties of the antitumor agent Sarcolysin, we have previously developed and characterized a dosage form representing its ester conjugate with decanol embedded in ultra-small phospholipid nanoparticles less than 30 nm in size ("Sarcolysin …
To improve the therapeutic properties of the antitumor agent Sarcolysin, we have previously developed and characterized a dosage form …
Melphalan Flufenamide (Melflufen): First Approval.
Dhillon S. Dhillon S. Drugs. 2021 Jun;81(8):963-969. doi: 10.1007/s40265-021-01522-0. Drugs. 2021. PMID: 33961277 Review.
It is an ethyl ester of a lipophilic dipeptide consisting of melphalan and para-fluoro-L-phenylalanine. Due to its lipophilicity, melphalan flufenamide is rapidly transported across the cell membrane and almost immediately hydrolyzed by aminopeptidases in the cytopl …
It is an ethyl ester of a lipophilic dipeptide consisting of melphalan and para-fluoro-L-phenylalanine. Due to its lipophilicity, …
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O, Mateos MV, Efebera YA, Paner A, Larocca A, Rodríguez-Otero P, Leleu X, Richardson PG. Nadeem O, et al. Drugs Today (Barc). 2022 Aug;58(8):407-423. doi: 10.1358/dot.2022.58.8.3367680. Drugs Today (Barc). 2022. PMID: 35983927 Review.
Patients with relapsed/refractory MM (RRMM), especially those with triple-class-refractory disease or poor-prognostic features, have substantially unmet needs for new therapies with novel mechanisms of action. Melphalan flufenamide (melflufen) is the first alkylating pepti …
Patients with relapsed/refractory MM (RRMM), especially those with triple-class-refractory disease or poor-prognostic features, have substan …
Melphalan.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1990 Jan;7(1):35-6. doi: 10.1177/104345429000700110. J Pediatr Oncol Nurs. 1990. PMID: 2363868 No abstract available.
Oral melphalan kinetics.
Alberts DS, Chang SY, Chen HS, Evans TL, Moon TE. Alberts DS, et al. Clin Pharmacol Ther. 1979 Dec;26(6):737-45. doi: 10.1002/cpt1979266737. Clin Pharmacol Ther. 1979. PMID: 498715
Oral melphalan had a mean plasma terminal phase half-life (t1/2) of 90 +/- 17 min. ...In a myeloma patient who took oral melphalan, no melphalan was found in plasma or urine up to 24 hr. Some instances of failure of tumor response to oral melphalan may …
Oral melphalan had a mean plasma terminal phase half-life (t1/2) of 90 +/- 17 min. ...In a myeloma patient who took oral melphalan …
Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
Gullbo J, Wallinder C, Tullberg M, Lövborg H, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. Gullbo J, et al. Mol Cancer Ther. 2003 Dec;2(12):1331-9. Mol Cancer Ther. 2003. PMID: 14707274
The tripeptide P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester) has been suggested as the main contributor to PTC activity. In contrast to its analogue melphalan, m-L-sarcolysin never reached clinical use. To allow a direct comparison, the correspond …
The tripeptide P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester) has been suggested as the main contributor to PTC activity. …
Melflufen for the treatment of multiple myeloma.
Ocio EM, Nadeem O, Schjesvold F, Gay F, Touzeau C, Dimopoulos MA, Richardson PG, Mateos MV. Ocio EM, et al. Expert Rev Clin Pharmacol. 2022 Apr;15(4):371-382. doi: 10.1080/17512433.2022.2075847. Epub 2022 Jun 19. Expert Rev Clin Pharmacol. 2022. PMID: 35723075
INTRODUCTION: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that takes advantage of increased aminopeptidase activity inside tumor cells to rapidly release alkylating agents therein. ...
INTRODUCTION: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that takes advantage of increased aminopep …
Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells.
Hansson J, Lewensohn R, Ringborg U. Hansson J, et al. Anticancer Res. 1991 Sep-Oct;11(5):1725-30. Anticancer Res. 1991. PMID: 1768043
We have compared the effects of melphalan, m-L-sarcolysin and PSF on human melanoma cell lines. PSF was 35-fold and 28-fold more toxic to RPMI 8322 melanoma cells than melphalan and m-L-sarcolysin, respectively. Similar differences in the cytotoxic eff …
We have compared the effects of melphalan, m-L-sarcolysin and PSF on human melanoma cell lines. PSF was 35-fold and 28-fold mo …
Vasculitis and melphalan.
Skehan MW, Bernath AM. Skehan MW, et al. JAMA. 1978 Dec 15;240(25):2733-4. doi: 10.1001/jama.1978.03290250037017. JAMA. 1978. PMID: 713003 No abstract available.
Sarcolysin and related compounds.
WHITE FR. WHITE FR. Cancer Chemother Rep. 1960 Feb;6:61-93. Cancer Chemother Rep. 1960. PMID: 13844348 No abstract available.
11,962 results
You have reached the last available page of results. Please see the User Guide for more information.